CN1178690C - Medicine for regulating immunity and its production method - Google Patents
Medicine for regulating immunity and its production method Download PDFInfo
- Publication number
- CN1178690C CN1178690C CNB021382719A CN02138271A CN1178690C CN 1178690 C CN1178690 C CN 1178690C CN B021382719 A CNB021382719 A CN B021382719A CN 02138271 A CN02138271 A CN 02138271A CN 1178690 C CN1178690 C CN 1178690C
- Authority
- CN
- China
- Prior art keywords
- medicine
- extractum
- present
- production
- immunoregulation medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a medicine for regulating immunity and a production method thereof. The medicine is in the form of granules prepared from the medicinal materials isogenous medicine and appetite of 1% to 97% of Chinese wolfberry fruit, 1% to 97% of astragalus root and 1% to 97% safflower according to proportion. The production method comprises the following steps that (1) after being mixed, the medicinal materials are soaked with water and are decocted twice; (2) decoction liquids are mixed and concentrated until 1 ml of decoction liquid contains 1g of crude drug; (3) ethanol is added until alcohol content reaches 30% to 50% on standing for 8 to 12 hours; (4) the decoction liquid is centrifugated to obtain a supernatant fluid, and the ethanol is recovered until the relative density is from 1.25 to 1.40 to prepare extractum; (5) after lactose, dextrin and corrigent are added, the extractum is granulated, dried and sieved, and the medicine of the present invention is obtained. The medicine of the present invention has the effect of regulating the immunity of human bodies. The medicine can be used for adjutant therapy of chemotherapy for patients suffering from phymatosis, and is suitable for people in old ages and weakness due to chronic diseases to take. The medicine has the advantages of unique formula, reliable therapeutic effect, low cost and no toxic or side effect.
Description
Technical field
The present invention relates to a kind of medicine production method, particularly relate to a kind of vegetable drug and be the production method of the immunoregulation medicament that raw material makes with integration of edible and medicinal herbs with immunoloregulation function.
Technical background
At present, still there are many problems in the immunomodulating quasi drugs manufacturing enterprise of China, and wherein most typical is that the product repetition is many, and scientific and technological content is low.Identical product even reach enterprise of hundreds of family and produce simultaneously, imitation mutually.Immunomodulating quasi drugs on the market belongs to traditional tonic of the first generation mostly now, and it is reasonable inadequately to fill a prescription, and drug effect is difficult to make definite evaluation.Therefore, be badly in need of developing fill a prescription reasonable, the definite novel immunomodulating quasi drugs of drug effect, to satisfy people's current consumption needs.
Summary of the invention
It is reasonable inadequately that the technical problem to be solved in the present invention is exactly existing immunomodulating quasi drugs prescription, and the problem that drug effect is definite inadequately provides a kind of production method of the new reliable immunoregulation medicament of drug effect for people.
Medicine production method of the present invention comprises the following steps:
(1) back that is soaked in water after by the weight ratio of Fructus Lycii 40%-60%, Radix Astragali 30%-50%, Flos Carthami 5%-15% above-mentioned three flavor crude drug being mixed decocts 2 times;
(2) merge decocting liquid, be condensed into every ml decocting liquid and contain the 1g crude drug;
(3) add ethanol, make to contain the alcohol amount and reach 30%-50%, left standstill 8-12 hour;
(4) after the centrifugal treating, get supernatant, reclaiming ethanol to relative density is 1.25-1.40, makes extractum;
(5) in extractum, add behind lactose, dextrin, the correctives granulate, dry, sieve, just make the finished particle agent.
The medicine that adopts the present invention's production has following advantage through zoopery and anthroposcopy:
1, the whole drug ofs choice of medicine of the present invention are eaten homologous natural plant crude drugs as raw material, utilize the comprehensive function of the Chinese medicine of respectively distinguishing the flavor of, and prevent and treat all kinds of diseases relevant with immunologic function disorder, and prescription novelty, uniqueness are nontoxic to human body.
2, curative effect is reliable, and medicine of the present invention has tangible immunoregulation effect, has good preventive and therapeutic effect to multiple with the immunologic function disorder diseases associated, and can be used for getting old and weak weakness due to chronic disease person and the tumour patient auxiliary treatment during chemicotherapy.
3, easy to use, with low cost.
The specific embodiment
Embodiment 1:
At first, take by weighing raw material by following proportioning:
Fructus Lycii 50Kg, Radix Astragali 35Kg, Flos Carthami 15Kg.
Secondly, process by following step:
1, after above-mentioned three flavor medical materials mix 10 times of (weight ratio, as follows) water gagings immersions of back adding, fried in shallow oil 1.5 hours, add 8 times of water gagings again and fried in shallow oil 1.0 hours;
2, merge twice decocting liquid, be condensed into every ml and contain the 1g crude drug;
3, add ethanol, make to contain the alcohol amount and reach 50%, left standstill 8 hours;
4, carry out centrifugal treating on butterfly sheet centrifuge, centrifuge speed is 5000rpm, centrifugal 20 minutes altogether;
5, get supernatant, reclaiming ethanol to relative density is 1.25 (80 ℃ of surveys), makes extractum;
6, the ratio in 5: 2: 0.05 adds lactose 106Kg, dextrin 42.5Kg, correctives 1.5Kg granulation, drying, sieves in gained extractum.
At last, carry out quantitative packing, seal, promptly make the finished particle agent.
Embodiment 2:
At first, take by weighing raw material by following proportioning:
Fructus Lycii 40Kg, Radix Astragali 50Kg, Flos Carthami 10Kg.
Secondly, process by embodiment 1 described method, its difference is as follows:
Add 12 times of water gagings when 1, decocting for the first time and fried in shallow oil 2 hours, add 10 times of water gagings for the second time and fried in shallow oil 1.5 hours.
2, collecting decoction is condensed into and adds ethanol after every ml contains the 1g crude drug, makes to contain the alcohol amount and reach 45%, leaves standstill 10 hours;
3, centrifuge speed is 6000rpm during centrifugal treating, and centrifugal treating is 30 minutes altogether;
4, reclaiming ethanol to relative density is 1.35 (80 ℃ of surveys).
5, the ratio in 6: 3: 0.1 adds lactose 99Kg, dextrin 49.5Kg, correctives 1.5Kg in gained extractum.At last, carry out quantitative packing, seal, promptly make the finished particle agent.
Embodiment 3
At first, take by weighing raw material by following proportioning:
Fructus Lycii 60Kg, Radix Astragali 35Kg, Flos Carthami 5Kg.
Secondly, process by embodiment 1 described method, its difference is as follows:
Add 8 times of water gagings when 1, decocting for the first time and fried in shallow oil 1 hour, add 6 times of water gagings for the second time and fried in shallow oil 0.5 hour.
2, collecting decoction is condensed into and adds ethanol after every ml contains the 1g crude drug, makes to contain the alcohol amount and reach 30%, leaves standstill 12 hours;
3, centrifuge speed is 7000rpm during centrifugal treating, and centrifugal treating is 15 minutes altogether;
4, reclaiming ethanol to relative density is 1.40 (80 ℃ of surveys)
5, the ratio in 8: 4: 0.15 adds lactose 99Kg, dextrin 49.4Kg, correctives 1.6Kg in above-mentioned extractum.
At last, carry out quantitative packing, seal, promptly make the finished particle agent.
More than three employed correctivess of embodiment be stevioside, certainly, also available other medicinal correctives.
The present invention is oral usually, each 3g-6g, and every 2-3 time, tumour patient can suitably increase consumption during chemicotherapy.
Provide below with the partial test result (seeing Table 1-6) who gives animal after the intermediate products extractum dilution of the present invention:
Table 1: the present invention is to mouse immune organ weight's influence
Dosed administration approach immune organ weight (mg)
(mg/Kg.d) spleen thymus
(1) adult mice
0 lumbar injection 92.4 ± 9.3-
25 * 7 lumbar injections 167.2 ± 10.3-
(2) aged mouse
0 irritates stomach-16.3 ± 5.2
4 * 180 irritate stomach-29.4 ± 6.3
Medication group and 0mg/Kg i.e. not medication group compare P＜0.01.
Table 1 is the result show, no matter to adults, still aged animal all can obviously increase immune organ weight on integral level in the present invention.
Table 2: animal intraperitoneal administration of the present invention is to the influence of mouse immune cell function
Dosage macrophage function T cell proliferation function natural killer cell function killer T cell function
(mg/Kg.d) (killing and wounding %) (the killing and wounding %) of (engulfing %) (cpm)
(1) adult mice
0 28 28410±3110 12 33
5×7 86 37354±2571 18 67
(3) aged mouse
0 - 6333±2371 - -
5×7 - 49028±4018 - -
Medication group and 0mg/Kg i.e. not medication group compare P＜0.01.
Table 2 is the result show, the present invention can not only obviously strengthen adult mouse macrophage, T lymphocyte, natural killer cell and killer T cell function on cellular level, also can reverse the aged mouse T lymphopoiesis function that is in low state.
Table 3: animal intraperitoneal administration of the present invention is to the influence of mouse lymphocyte number
Dosage periphery blood T lymphocyte antibody forming cell
(mg/Kg.d) (％) (PFC)
(1) adult mice
0 64.2±3.2 -
5×7 81.3±5.4 -
(2) aged mouse
0 - 126.5±30.1
1×7 - 325.4±50.5
Medication group and 0mg/Kg i.e. not medication group compare P＜0.01.
Annotate: adult mice antibody forming cell (PFC) is 231.4 ± 51.0.
Table 3 is the result show, the present invention can not only obviously improve adult mice periphery blood T lymphocyte number on cellular level, and aged mouse antibody forming cell number lowly also had an obvious reverse effect.
Table 4: gastric infusion of the present invention produces the influence of interleukin-2 to aged mouse T lymphocyte
Group dosage interleukin-2 generative capacity
(mg/Kg.d) (cpm)
Adult mice matched group 0 22221 ± 2340
Aged mouse matched group 0 10479 ± 3230
Aged mouse medication group 50 * 7 21717 ± 1650
The aged mouse matched group is compared with the adult mice matched group, P＜0.01; Aged mouse medication group and aged mouse matched group compare, P＜0.01.
Table 4 is the result show, the present invention can obviously promote aged mouse T lymphocyte to produce interleukin-2 on molecular level.
Table 5: the influence that the mice peripheral blood neutrophil that gastric infusion of the present invention causes cyclophosphamide reduces
Group number of animals peripheral blood neutrophil
(only) is (individual/mm
3)
Normal control group 20 1822 ± 550
Cyclophosphamide group 20 936 ± 235
Cyclophosphamide+of the present invention group 20 2913 ± 1159
The cyclophosphamide group is compared with the normal control group, P＜0.05; Cyclophosphamide+of the present invention group is compared P＜0.01 with the cyclophosphamide group.
Table 5 is the result show, the present invention has obvious reverse effect to the minimizing of the mice peripheral blood neutrophil number that the chemotherapeutics cyclophosphamide causes.
Table 6: intraperitoneal administration of the present invention is to the influence of mice transplanted tumor growth
The heavy tumour inhibiting rate of dosage tumor
(mg/Kg.d) (g) (％)
(1) solid type hepatocarcinoma
0 1.16±0.54 -
6.25×10 0.61±0.33 51
(2) S180 sarcoma
0 4.00±0.93 -
12.50×10 2.60±1.38 36
Medication group and 0mg/Kg i.e. not medication group compare P＜0.05.
Table 6 is the result show, the present invention has certain inhibitory action to the transplanted tumor of laboratory animal in vivo.
Claims (6)
1, a kind of production method of immunoregulation medicament is characterized in that it comprises the steps:
(1) back that is soaked in water after by the weight ratio of Fructus Lycii 40%-60%, Radix Astragali 30%-50%, Flos Carthami 5%-15% above-mentioned three flavor crude drug being mixed decocts 2 times;
(2) decocting liquid is merged, be condensed into every ml decocting liquid and contain the 1g crude drug;
(3) add ethanol, make to contain the alcohol amount and reach 30%-50%, left standstill 8-12 hour;
(4) after the centrifugal treating, get supernatant, reclaiming ethanol to relative density is 1.25-1.40, makes extractum;
(5) in extractum, add behind lactose, dextrin and the correctives granulate, dry, sieve, just make final finished particle agent;
2, the method for production immunoregulation medicament according to claim 1 adds 2 times of water 8-1 for the first time when it is characterized in that decocting, fried in shallow oil 1-2 hour; Add for the second time water 6-10 doubly, fried in shallow oil 0.5-1.5 hour.
3, the method for production immunoregulation medicament according to claim 1, centrifugal rotational speed is 4000-7000rpm when it is characterized in that centrifugal treating, centrifugation time is 20-40 minute;
4, the method for production immunoregulation medicament according to claim 1, the relative density the when relative density that it is characterized in that extractum is 80 ℃.
5, the method for production immunoregulation medicament according to claim 1, the weight ratio of the lactose that it is characterized in that adding, dextrin, correctives is 5-8: 2-4: 0.05-0.15.
6, a kind of immunoregulation medicament of producing according to the described method of claim 1, the weight ratio that it is characterized in that preparing the used crude drug of finished product granule and the lactose, dextrin and the correctives that are added is 1: 1.5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021382719A CN1178690C (en) | 2002-09-13 | 2002-09-13 | Medicine for regulating immunity and its production method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021382719A CN1178690C (en) | 2002-09-13 | 2002-09-13 | Medicine for regulating immunity and its production method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1410100A CN1410100A (en) | 2003-04-16 |
| CN1178690C true CN1178690C (en) | 2004-12-08 |
Family
ID=4749379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021382719A Expired - Lifetime CN1178690C (en) | 2002-09-13 | 2002-09-13 | Medicine for regulating immunity and its production method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1178690C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103127316B (en) * | 2013-02-06 | 2016-01-13 | 天津市嘉沃科技有限公司 | A kind of preparation method of earthworm medicinal liquor |
| CN112089770A (en) * | 2020-10-02 | 2020-12-18 | 辽宁泰阳医药科技开发有限公司 | Composition capable of improving immunity and preparation method thereof |
-
2002
- 2002-09-13 CN CNB021382719A patent/CN1178690C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1410100A (en) | 2003-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1836720A (en) | Chinese medicine composition for treating arthritis or gout and preparing method thereof | |
| CN1861163A (en) | Traditional Chinese medicine composition for treating kidney-yang deficiency and deficiency of vital energy and blood, its prepn. process | |
| CN101053621A (en) | Traditional Chinese medicinal composition for treating obesity and its preparation method | |
| CN1666754A (en) | Semi-solid oral formulation of Chinese medicine | |
| CN1297291C (en) | Medicine for abstaining from drug addiction and its preparation | |
| CN1561994A (en) | Medicinal compositon containing artemisine extract for treating rheumatoid arthritis and immunologic disease | |
| CN1895619A (en) | Chinese-medicinal composition for preventing and treating liver disease and its preparation | |
| CN1850255A (en) | Medicine composition and preparing method | |
| CN1895546A (en) | Lycium chinensis polyose medicinal composition with therapeutic and health-care functions | |
| CN1178690C (en) | Medicine for regulating immunity and its production method | |
| CN1051714C (en) | Traditional Chinese patent medicine for strengthening spleen and appetizing and its preparation method | |
| CN1060657C (en) | Nourishing medicine for preventing and curing toxic and side effect after tumor radiotherapy and chemotherapy and preparation method | |
| CN1830469A (en) | Medicine for improving sleep quality and its preparation method | |
| CN1264543C (en) | Medicine for treating baby and child diarrhea and its preparation method | |
| CN1857684A (en) | Compound Chinese medicine preparation for removing toxic matter, dispersing blood clots and strengthing body's resistance and its preparaing process | |
| CN1172715C (en) | Medicine for antiimmune disorder and its production technology | |
| CN1569095A (en) | Medicine for treating cerebral infarction | |
| CN1799603A (en) | Chinese traditional medicine composition for treating rheumatic or rheumatoid disease and preparation method thereof | |
| CN1251751C (en) | Chinese traditional medicine for treating chronic liver disease and anti hepatic fibrosis | |
| CN1973850A (en) | Medicine composition for treating allergic rhinitis and its prepn process | |
| CN101032540A (en) | Medicine composition for curing arthritis and the preparing method and purpose thereof | |
| CN1274353C (en) | Medication for curing children's infantile malnutrition and preparation method | |
| CN1899387A (en) | Method for preventing and treating child convulsion and its preparing method | |
| CN1515274A (en) | Medicine for curing coronary heart disease | |
| CN1895402A (en) | Chinese-medicinal preparation for improving lactation and its preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20041208 |